Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-blind Randomized Study of the Efficacy and Safety of the GNR-086 (Canakinumab Proposed Biosimilar) in Comparison With the Ilaris®, Conducted in Parallel Groups of Patients With Adult-onset Still's Disease

NCT06497491 is registered in ClinicalTrials.gov with AO GENERIUM as lead sponsor.

NCT NCT06497491
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06497491 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-blind Randomized Study of the Efficacy and Safety of the GNR-086 (Canakinumab Proposed Biosimilar) in Comparison With the Ilaris®, Conducted in Parallel Groups of Patients With Adult-onset Still's Disease
Lead sponsor
AO GENERIUM
Phase
Phase 3
Overall status
Completed
Start date
December 12, 2023
Completion date
July 10, 2025
Enrollment
118 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

still's disease adult onset